Daily EPS Performer Reports

Stocks detected early by our EPS revision screener — and how they performed.

2026-09-01
RNXTINTZBRZECRCLDFDV

RNXT Leads EPS Revision Surge: +15.6% in 3 Days

RNXT jumped 15.6% from $1.67 to $1.93 after its next-year EPS estimate was revised upward by 5.6 percentage points (41.1% to 46.7%) on August 28. INTZ followed with an 11.1% gain on a 9.9pp upward revision. These moves came despite no earnings-related news, highlighting the market's recognition of improved earnings fundamentals.

Read analysis →
2026-08-31
CRWDRNXTSLBINTZBRZE

CRWD Leads EPS Revision Surge With 21.1% Jump as Software Stocks Rally

CrowdStrike (CRWD) jumped 21.1% (from $190.68 to $231.00) after its next-year EPS growth estimate rose to 26.5%, with record-breaking earnings reinforcing the move. Other strong performers included RenovoRx (RNXT) up 15.6% on a 5.6-point EPS revision boost, and SLB (SLB) gaining 11.3% on a 28.9% EPS growth outlook. The EPS revision screener flagged these names early, and price action confirmed the upgraded fundamentals.

Read analysis →
2026-08-29
AZTREBSCRWDBRZEHUBS

AZTR jumps 38.5% as EPS revision boosts small-cap healthcare AI play

AZTR surged 38.5% from $0.13 to $0.18 in the six sessions after analysts raised its next-year EPS estimate from 59.6% to 68.0% on August 21, the strongest gain of the five stocks highlighted. CRWD leapt 14.5% to $218.40 following record quarterly results, while EBS climbed 16.3% to $5.91 on the back of a 191.0% EPS growth outlook. The technology trio (CRWD, BRZE, HUBS) advanced between 8.6% and 14.5%, reflecting persistent investor appetite for AI/cloud software names.

Read analysis →
2026-08-28
AZTRCRWDEBSXMTRCYPH

AZTR Leads EPS Revision Surge with 46% Gain; CRWD Jumps 19.6%

Stocks with upward EPS estimate revisions delivered strong gains during the week ended August 28, 2026. Azitra (AZTR) led with a 46.1% surge after its forward EPS revision rose 8.4pp, while CrowdStrike (CRWD) gained 19.6% following record earnings and a raised outlook. Xometry (XMTR), Emergent Biosolutions (EBS), and Cypherpunk Technologies (CYPH) also posted double-digit gains, signaling broad momentum in earnings-driven plays.

Read analysis →
2026-08-27
CYPHAZTRBLSHEBSGEMI

CYPH Soars 52% as EPS Revisions Hit 254.6%

Cypherpunk Technologies (CYPH) led the pack with a 52.3% surge to $1.63 after its next-year EPS growth estimate was revised upward by 172.2 percentage points to 254.6% on August 19. Azitra (AZTR), Bullish (BLSH), Emergent BioSolutions (EBS), and Gemini Space Station (GEMI) also posted double-digit gains, driven by positive earnings revisions and sector momentum.

Read analysis →
2026-08-26
CYPHMSTRPREAZTRIDAI

CYPH Soars 52% as EPS Revisions Signal Breakout in Healthcare AI

Small-cap healthcare AI play CYPH led the pack with a 52.3% surge from $1.07 to $1.63 after analysts raised its next-year EPS growth estimate by a staggering 172.2 percentage points to 254.6%. MSTR and PRE also gained 33.1% and 32.9% respectively, driven by Bitcoin's recovery above $80K and insider purchases following strong Q2 results.

Read analysis →
2026-08-25
CYPHMSTRDEFTSECZNFGC

CYPH Soars 53% as EPS Revisions Signal Explosive Growth

Cypherpunk Technologies (CYPH) surged 53.3% from $1.07 to $1.64 in under a week after the screener flagged a massive next-year EPS revision from 82.3% to 254.6%. MSTR climbed 37.1% after Canaccord raised its price target to $175, while DEFT gained 27.7% despite a pullback in revenue, reflecting strong inflows and a 1550% EPS growth outlook.

Read analysis →
2026-08-24
CYPHMSTRDEFTTNONIDAI

CYPH Soars 57% After EPS Estimate Triples to 254.6%

CYPH led with a 57.0% surge after its next-year EPS growth estimate jumped from 82.3% to 254.6% on August 19. MSTR rallied 32.5% following a $2 billion capital raise that expanded its bitcoin-buying firepower, while DEFT, TNON, and IDAI logged gains between 22.9% and 31.9% as their own EPS revisions and catalysts aligned.

Read analysis →
2026-08-21
TEMTNONMSTRIDAISLS

Tempus AI Soars 39.5% on Big EPS Revision; MSTR Jumps 28.9% as Bitcoin Hits $77K

Today's top performers were led by Tempus AI (TEM), which surged 39.5% from $52.10 to $72.69 after analysts raised its forward EPS growth estimate by 16.1 percentage points on August 14. Tenon Medical (TNON) gained 38.8% following a 21.0pp EPS revision, while Strategy (MSTR) advanced 28.9% to $119.25 on Bitcoin's rally to $77,000, which flipped its Bitcoin holdings to a $1.4 billion unrealized profit.

Read analysis →
2026-08-20
TNONTEMINTSHBIOARGX

TNON leads healthcare surge +43.7% as EPS revisions power gains

Healthcare stocks dominated today's gainers after forward EPS estimates were revised sharply higher. Tenon Medical (TNON) jumped 43.7% to $7.07, Tempus AI (TEM) gained 27.9% to $66.65, and Intensity Therapeutics (INTS) rose 23.2% to $4.88. Harvard Bioscience (HBIO) climbed 22.4% to $7.55 after its Q2 beat and raised guidance, while Argenx (ARGX) advanced 21.9% to $1,038.12 on positive Phase 3 data.

Read analysis →
2026-08-19
ACHVKURAARGXREEDSLS

EPS Revisions Trigger Double-Digit Gains: ACHV Leads 26.0% Surge

Five stocks detected by our EPS revision screener posted double-digit gains: ACHV surged 26.0%, KURA +24.2%, ARGX +21.3%, REED +20.6%, and SLS +17.7%. Each was flagged after a significant upward EPS estimate revision, with earnings or trial data reinforcing the move.

Read analysis →
2026-08-18
SNDKRCELREEDKURAARGX

Sandisk Surges 32.7% After EPS Revision; ARGX, RCEL Rally

Sandisk (SNDK) jumped 32.7% from $1,224.78 to $1,625.78 after next-year EPS growth estimates hit 25.5%, amplified by JPMorgan's $2,250 price target and analyst comparisons to Micron. AVITA Medical (RCEL) climbed 29.6% on a 1.4pp EPS revision to 57.2% growth, supported by strong PermeaDerm trial results. Argenx (ARGX) gained 16.6% following positive Phase 3 ALKIVIA topline data in autoimmune myositis.

Read analysis →
2026-08-17
SNDKCLMTACBNBRREED

SNDK Soars 45.9% After EPS Revision, AI Memory Boom Fuels Rally

Sandisk (SNDK) led the gains, jumping 45.9% to $1,786.85 following an EPS revision and analyst target hikes, while Calumet (CLMT) rose 22.5% on strong base oil market dynamics. Aurora Cannabis (ACB) gained 20.4% on EPS growth of 161.8%, and Nabors (NBR) and Reed's (REED) posted double-digit gains driven by EPS revisions and operational improvements.

Read analysis →
2026-08-14
SHAZSNDKMYONYXHACB

SHAZ Soars 53.6% on AI Capacity Surge; SNDK, ACB Rally on EPS Revisions

SHAZ jumped 53.6% to $76.46 after its EPS growth estimate hit 86.2%, fueled by an AI capacity surge to 212MW and a $4.9B NVIDIA deal. SNDK gained 35.4% to $1641.11 on a 25.6% EPS growth estimate, with JPMorgan bullishness outweighing caution. ACB rose 23.5% to $3.68 after its EPS growth estimate jumped 16.1pp to 107.5%.

Read analysis →
2026-08-13
SHAZACBSNDKCLMTNYXH

SHAZ Surges 44.6% on AI Capacity Expansion; SNDK, ACB, CLMT, NYXH Follow

Shares of SharonAI Holdings (SHAZ) jumped 44.6% since August 7, driven by a massive AI capacity expansion and a $4.9 billion NVIDIA collaboration. Sandisk (SNDK) climbed 26.1% after unveiling aggressive long-term margin targets, while Aurora Cannabis (ACB) gained 27.2% following an EPS estimate revision and shareholder approval. Calumet (CLMT) and Nyxoah (NYXH) also posted double-digit gains on robust earnings and strategic developments.

Read analysis →
2026-08-12
SHAZCSAIACBRDWMBRX

SHAZ Soars 37.5% as AI Capacity Surges; Top EPS Revision Gainers

Stocks with upward EPS estimate revisions surged this week, led by SharonAI Holdings (SHAZ) up 37.5% after reporting a surge in AI capacity to 212MW and a $4.9B NVIDIA collaboration. Aurora Cannabis (ACB) gained 28.2% following an EPS revision boost and strong international revenue, while Redwire (RDW) rose 26.9% on defense sector momentum. The moves confirm the market's validation of improved earnings outlooks, especially in AI and defense.

Read analysis →
2026-08-11
REAXCSAIURDWDC

REAX surges 41% as EPS estimate spikes; Unity jumps 31%

Shares of The Real Brokerage (REAX) jumped 41.1% to $2.30 after next-year EPS growth estimates exploded from 650% to 1900%, reinforced by record Q2 revenue and agent count. Unity Software (U) climbed 31.4% to $43.87 following a Q2 beat and multiple analyst upgrades, while Cloudastructure (CSAI) rose 35.5%, Redwire (RDW) gained 27.1%, and Dakota Gold (DC) advanced 25.5%.

Read analysis →
2026-08-10
HZOCSAIREAXEQXU

HZO Soars 51% on EPS Revision, Leads EPS Screener Winners

MarineMax (HZO) jumped 51.2% to $52.12 after the screener detected a 122.7% next-year EPS growth revision on August 2. Real Brokerage (REAX) gained 31.3% following a 1250pp EPS growth estimate hike and record Q2 revenue of $700.6M. Unity (U) rose 29.1% on a 157.9% EPS growth revision, confirmed by analyst upgrades citing Vector ad platform momentum.

Read analysis →
2026-08-07
CSAIAAOIPUBMINSMLUNR

CSAI Soars 80.7% as EPS Revisions Fuel Rally; AAOI Up 43.8%

Cloudastructure (CSAI) surged 80.7% from $3.94 to $7.12 after the screener flagged a 37.5% next-year EPS growth estimate, with no specific news catalyst. Applied Optoelectronics (AAOI) jumped 43.8% to $135.63 following record Q2 revenue and raised guidance, reinforcing a 454.2% EPS growth estimate. PubMatic (PUBM) gained 41.1% to $17.78, while Insmed (INSM) climbed 33.0% to $131.10 on strong BRINSUPRI sales and a raised outlook.

Read analysis →
2026-08-04
ALABAAOIASTSNDLSFCEL

ALAB +44.8% Leads EPS-Revision Screeners on July 29

On July 29-31, the EPS-revision screener flagged five stocks whose next-year growth estimates were raised. ALAB led with a 44.8% gain to $361.67, followed by AAOI (+39.6% to $131.63) and ASTS (+32.6% to $70.31). Q2 beat-and-raise reports from ALAB and SpaceX-led sector momentum reinforced the moves.

Read analysis →
2026-07-31
NDLSFFAIOPTTKNSAKC

NDLS +30.7% Leads EPS Revision Gainers; FFAI +28.1% Follows

Our EPS revision screener caught five stocks whose forward earnings estimates were rising, and they have since delivered double-digit gains. Top performer NDLS jumped 30.7% to $18.62 after its next-year EPS growth estimate surged 125.0 percentage points to 309.1%. FFAI added 28.1% to $5.93, KNSA gained 17.9% to $74.34, OPTT rose 20.0% to $0.18, and KC climbed 17.7% to $11.15.

Read analysis →
2026-07-30
PMNKNSANDLSBZUNATEC

PMN Jumps 27.3% on EPS Revision and Alzheimer's Trial Data; KNSA, NDLS Follow

ProMIS Neurosciences (PMN) surged 27.3% after its EPS growth estimate was revised to 27.1% and positive Alzheimer's trial safety data reinforced the outlook. Kiniksa (KNSA) gained 24.0% following a 39.7% EPS growth estimate revision and strong Q2 earnings. Noodles & Company (NDLS) added 23.4% after a massive EPS growth estimate jump from 184.1% to 309.1%.

Read analysis →
2026-07-29
KNSAAMCBZUNCLFATEC

KNSA Surges 28% on EPS Revision, Record Revenue; AMC, BZUN, CLF Also Climb

Kiniksa Pharmaceuticals (KNSA) led with a 28.3% gain after its forward EPS growth estimate was revised to 39.7% and Q2 revenue hit a record $243.6M. AMC Entertainment jumped 25% on a 14.2pp EPS revision and record Q2 revenue of $1.6B. Cleveland-Cliffs (CLF) rose 23% after analysts lifted its EPS growth estimate to 246.8% and Q2 EBITDA tripled.

Read analysis →
2026-07-28
CLFKNSAAMCBZUNGENI

CLF Surges 33.4% After EPS Revision; Steel Sector Leads

Cleveland-Cliffs (CLF) jumped 33.4% after analysts raised its EPS growth estimate from 198.6% to 235.3%, driven by a strong Q3 outlook and Section 232 tariffs. Kiniksa (KNSA) rose 26.0% on raised ARCALYST sales guidance, while AMC gained 21.4% on record Q2 revenue. The EPS revision screener caught these moves early across steel, biotech, and cinema sectors.

Read analysis →
2026-07-27
CLFCHGGGRSDGENIAMC

Cleveland-Cliffs (CLF) Jumps 36.4% on EPS Revision and Strong Q3 Outlook

Today’s top performers include Cleveland-Cliffs (CLF) surging 36.4% after its EPS growth estimate was raised 36.7 percentage points to 235.3%, reinforced by a strong Q2 earnings report and Q3 guidance that projects more than doubling EBITDA. Chegg (CHGG) and Grandstand (GRSD) rose 20.7% and 15.4% respectively on upward EPS revisions to 50.0% and 91.7%, while AMC Entertainment and Genius Sports each gained 14.1% on estimate upgrades and record-breaking results.

Read analysis →
2026-07-24
CLFFCELCHGGIPSW

CLF Leads EPS Revision Screeners with 32.9% Surge on Strong Steel Outlook

Cleveland-Cliffs (CLF) surged 32.9% after analysts boosted its EPS growth estimate by 36.7 percentage points to 235.3%, following a Q2 earnings beat and upbeat guidance. FuelCell Energy (FCEL) rose 23.2% on a revision to 52.8% EPS growth, while Chegg (CHGG) gained 17.1% on a 50% estimate. International Paper (IP) and Smurfit WestRock (SW) also rallied 12.2% and 9.6% respectively on EPS estimate upgrades.

Read analysis →
2026-07-23
FCELCLFOBECHGGMU

Top EPS Revision Plays: FCEL Surges 35%, CLF Jumps 22% on Earnings Beat

Stocks with upward EPS estimate revisions delivered strong gains this week. FCEL rose 35% after its growth estimate was raised to 52.8%. CLF gained 22% on a 36.7 percentage point revision and a Q2 earnings beat that tripled EBITDA. MU advanced 16.6% despite chip sector headwinds, supported by a 110.1% growth estimate.

Read analysis →
2026-07-22
FWRDRCELAEHRAIRSLITE

Forward Air (FWRD) surges 25.6% as EPS revision sparks rally

Upward EPS revisions drove significant gains. Forward Air (FWRD) climbed 25.6% after its estimate rose from 69.4% to 78.0%, AVITA Medical (RCEL) gained 22.9% on a revision to 48.4% EPS growth, and Aehr Test Systems (AEHR) added 15.4% as its estimate jumped to 119.6%. The rally underscores market appetite for estimate upgrades in industrials, healthcare, and technology.

Read analysis →
2026-07-21
FWRDRCELAEHRAIRSCLMT

FWRD Leads EPS Revision Surge with 26.7% Gain; AEHR, RCEL Follow

Forward Air Corp (FWRD) surged 26.7% after its forward EPS growth estimate was raised from 69.4% to 78.0% on July 14. Aehr Test Systems (AEHR) gained 22.0% following a 20.0pp revision to 119.6%, backed by multiple analyst upgrades. AVITA Medical (RCEL) added 26.6% on a revised EPS estimate of 48.4%, while Airsculpt Technologies (AIRS) and Calumet (CLMT) posted double-digit gains on EPS upgrades.

Read analysis →
2026-07-20
RCELAIRSTNDMCLMTIQ

RCEL leads with 27.9% gain on EPS revision; other healthcare stocks follow

Five stocks detected by the EPS revision screener posted strong gains, led by RCEL (+27.9%) and AIRS (+13.8%). Each saw upward revisions to forward EPS growth estimates, with RCEL's estimate hitting 48.4% and TNDM's revised from 113.1% to 119.8%. The moves occurred despite limited company-specific news, underscoring the market's focus on earnings momentum.

Read analysis →